Biogen on Twitter: "Chris Henderson, VP, Neuromuscular and Movement Disorders Research Unit, highlights the importance of an early Progressive Supranuclear Palsy (PSP) diagnosis #PSPAwareness https://t.co/xDnZaZYYhT" / Twitter
Biogen Study - CurePSP
PSPH (Human) Recombinant Protein (Q01) - BIOGEN Científica
Biogen on Twitter: "#DYK progressive supranuclear palsy (#PSP) wasn't discovered until 1963 due to its resemblance to Parkinson's disease? #PSPAwarenessMonth https://t.co/59rxSezyHe" / Twitter
admin – Page 2 – PSP Society of Canada
Amanda Pereira Silva - Patient Services Analyst Pl - Biogen | LinkedIn
Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
Characteristics of patients with progressive supranuclear palsy (PSP) in US health insurance claims data Progressive supranuclea
Corio PSP™ – Detox RejuveNation
These Clinical Study Results are provided for informational purposes only. The study listed may include approved and non
Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy | Biogen
Biogen on Twitter: "We're dedicated to advancing research and development for movement disorders like progressive supranuclear palsy (#PSP). https://t.co/7NOueg0df4" / Twitter
Acompañamos a... - Pharmexx Argentina part of Ashfield Group | Facebook
Biogen abandons tau antibody for Alzheimer's after phase 2 miss | pharmaphorum
PSP — Coleen Heaver
☑️Biogen México — Supplier from Mexico, experience with UNOPS — Health, Laboratory & Measurement, Research, Science & Innovation sectors — DevelopmentAid
What's in Biogen's Clinical Pipeline?
AbbVie Discontinued a Drug Trial. Biogen Stock Is Falling. | Barron's
Biogen looks to M&A to overcome competition to its MS franchise | Fierce Pharma
Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's | Fierce Biotech
Medscape Neurology - After disappointing trial results, Biogen will discontinue development of gosuranemab for PSP and other primary tauopathies. http://ms.spr.ly/6182Tn3Cq | Facebook
Carla Erba - Latam PSP Lead - Biogen | LinkedIn
Biogen Ends Trial of Its Drug for PSP - CurePSP
Biogen on Twitter: "#DYK…Progressive supranuclear palsy (#PSP) is a neurodegenerative disorder that affects the brain cells controlling balance, walking, coordination, eye movement, speech, swallowing and thinking. #AANAM https://t.co/uYb551MjJi" / Twitter
Biogen pays $300M to Bristol-Myers for another potential Alzheimer's drug - Boston Business Journal
FAQ on FDA Approval of Aducanumab - CurePSP
Biogen Stock Rebounds After Impressive Q3 Earnings | InvestorPlace
